MetaCap

Annovis Bio (ANVS) vs Apollomics (APLM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apollomics (APLM) has outperformed Annovis Bio (ANVS) over the past year, gaining 7.4% versus a loss of 81.2%. Over five years, ANVS leads with a -97.2% price change compared with -98.4% for APLM. Apollomics is the larger company by market cap ($45.3 million vs $44.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANVS-81.23%APLM+7.43%
+103%+6%-91%
Nov 21, 20251 yearNov 20, 2026
ANVS-97.24%APLM-98.43%
+157%+22%-112%
Nov 22, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANVS versus APLM key metrics
MetricANVSAPLM
Share price$0.7113$15.54
Market cap$44.12M$45.28M
1-day change-4.96%-6.92%
YTD return-79.44%-16.90%
1-year return-81.23%+7.43%
5-year return-97.24%-98.43%
EPS (TTM)$-1.55$-0.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Net income (latest FY)$-28.85M$-53.86M
52-week high$5.50$28.29
52-week low$0.62$12.58
Distance from 52-week high-87.07%-45.09%
Analyst consensusnone—
Avg. price target upside+1376.17%—
Average volume1.82M11.07K
Shares outstanding62.02M2.91M
Employees714
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • APLM has outperformed ANVS by 88.7 percentage points over the past year.

About Annovis Bio

ANVS stock →

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Apollomics

APLM stock →

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

ANVS vs APLM FAQ

Which is bigger, Annovis Bio or Apollomics?

Apollomics (APLM) is larger, with a market capitalization of $45.28M compared with $44.12M for Annovis Bio (ANVS).

Which stock has performed better over the past year, ANVS or APLM?

APLM returned +7.43% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.

Are Annovis Bio and Apollomics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons